

Swing Therapeutics Achieved 97% Patient Compliance with ePRO



Highlights

- ✔ Swing Therapeutics used Medrio ePRO in a proof-of-concept DCT hybrid study.
- ✔ Site reaction was positive due to ease of scheduling and convenience for patients.
- ✔ The study achieved 97% patient compliance.

Background

Swing Therapeutics leveraged Medrio ePRO in a proof-of-concept for a decentralized hybrid study. Electronic Patient-Reported Outcomes (ePRO) technology was used to assess the results of varying digital therapies and the feasibility of conducting a largely virtual clinical study in a fibromyalgia population. Due to the ePRO ease of use, SMS notifications, and bring-your-own-device (BYOD) model, the pilot study was able to achieve 97% patient compliance. This success was paired with a significant increase in patient engagement and reduction of site burden.

Swing Therapeutics creates evidence backed digital treatments to help people with chronic conditions live their best lives. By investing in technology that patients and sites prefer, they are putting that mission into practice.

Challenges:

- ⦿ Feasibility of conducting a largely virtual trial
- ⦿ Patient compliance in a remote setting
- ⦿ Site preparedness and training

Why Medrio:

- ⦿ BYOD ePRO model
- ⦿ SMS and email alerts
- ⦿ Flexible workflows that support remote and in-clinic data collection

The Results:

- ⦿ 97% patient compliance
- ⦿ Increased site productivity
- ⦿ Increased patient engagement

“We chose a bring-your-own-device model because we wanted patients to be able to use the phone that they use every day for their digital treatment to ensure that it was always accessible.”

— Nicolette Vega,
Clinical Project Manager
at Swing Therapeutics

The Details

Swing Therapeutics was looking to see if a remote trial would be feasible for patients and sites. To be successful they would have to test new technologies and determined that a BYOD (bring-your-own device) approach for ePRO (Electronic Patient-Reported Outcomes) and the option for telehealth site visits would be their best path forward.

Why BYOD?

In this proof-of-concept, observational study participants were submitting data over the course of 12-14 weeks (inclusive of screening). Electronic Patient-Reported Outcomes (ePRO) were collected weekly, as well as additional assessments at weeks 4, 8, and 12. The hybrid study consisted of a single in-clinic visit with additional visits conducted primarily remotely. All ePROs were collected remotely with the device of their choosing. In order to remind patients to report electronically, Swing Therapeutics utilized Medrio ePRO's alerting function through email and SMS texting.

“We chose a bring-your-own-device model because we wanted patients to be able to use the phone that they use every day for their digital treatment to ensure that it was always accessible,” explained Nicolette Vega, Clinical Project Manager at Swing Therapeutics. “Most people own smartphones now, and the digital therapy application could be installed on any recent smartphone.”


The Site Reaction

The site reaction was positive. Follow-up visits were conducted either through video conference or by phone, and sites reported that they preferred telehealth visits over in-person visits due to the ease of scheduling and convenience for patients.

“We learned that sponsor-led protocol training is critical. There were a lot of moving parts in this study. On a site level, they were responsible for the in-person visits, telehealth calls, and compliance follow-up,” detailed Vega. “At the participant level, they had to complete sessions in their digital therapy application daily and complete ePRO questionnaires weekly via Medrio’s patient portal. It was important that the study staff understood the difference between the two systems and who to contact for quick issue resolution.”

The Results

Swing Therapeutics creates evidence backed digital treatments to help people with chronic conditions live their best lives. By investing in technology that patients and sites prefer, they are putting that mission into practice. This study saw high patient engagement along with 97% patient compliance by utilizing ePRO SMS alerts and email notifications. Sites were able to collect patient data remotely and conduct required visits virtually. This combination resulted in a reduced administrative burden on the site, which allowed for timely data collection and analysis and an overall positive experience for the site.



This study saw high patient engagement along with 97% patient compliance by utilizing ePRO SMS alerts and email notifications.

ABOUT SWING THERAPEUTICS

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective. Their focus is on tackling autoimmune conditions and chronic overlapping pain conditions (COPCs) like fibromyalgia where central pain sensitization is a significant factor. The company is investing in research to support the development and validation of its pipeline of prescription-based digital therapies. Swing Therapeutics’ near-term goal is to validate its digital program for the treatment of fibromyalgia and bring it to market as an FDA-cleared, prescription digital therapeutic. For more information visit swingtherapeutics.com.

ABOUT MEDRIO

At Medrio, we know that it takes a global village to achieve a healthier world. Our leading eClinical Data solutions have helped sponsors, CROs, and sites from all trial phases and therapeutic areas secure over 770 regulatory approvals. Whether conducting traditional, hybrid, or fully-virtual trials—our adaptive platform of EDC, DDC, eConsent, RTSM, and ePRO/eCOA help streamline your studies, without compromising data quality. And our experts are on-call 24/7 to help you solve your most pressing needs. Discover the Medrio difference and learn more at medrio.com.